Literature DB >> 11866008

Clinical significance of histological classification of idiopathic interstitial pneumonia.

K R Flaherty1, G B Toews, W D Travis, T V Colby, E A Kazerooni, B H Gross, A Jain, R L Strawderman, R Paine, A Flint, J P Lynch, F J Martinez.   

Abstract

Patients with idiopathic interstitial pneumonias (IIPs) can be subdivided into groups based on the histological appearance of lung tissue obtained by surgical biopsy. The quantitative impact of histological diagnosis, baseline factors and response to therapy on survival has not been evaluated. Surgical lung biopsy specimens from 168 patients with suspected IIP were reviewed according to the latest diagnostic criteria. The impact of baseline clinical, physiological, radiographic and histological features on survival was evaluated using Cox regression analysis. The predictive value of honeycombing on high-resolution computed tomography (HRCT) as a surrogate marker for usual interstitial pneumonia (UIP) was examined. The response to therapy and survival of 39 patients treated prospectively with high-dose prednisone was evaluated. The presence of UIP was the most important factor influencing mortality. The risk ratio of mortality when UIP was present was 28.46 (95% confidence interval (CI) 5.5-148.0; p=0.0001) after controlling for patient age, duration of symptoms, radiographic appearance, pulmonary physiology, smoking history and sex. Honeycombing on HRCT indicated the presence of UIP with a sensitivity of 90% and specificity of 86%. Patients with nonspecific interstitial pneumonia were more likely to respond or remain stable (9 of 10) compared to patients with UIP (14 of 29) after treatment with prednisone. Patients remaining stable had the best prognosis. The risk ratio of mortality for stable patients compared to nonresponders was 0.32 (95% CI 0.11-0.93; p=0.04) in all patients and 0.33 (95% CI 0.12-0.96; p=0.04) in patients with UIP. The histological diagnosis of usual interstitial pneumonia is the most important factor determining survival in patients with suspected idiopathic interstitial pneumonia. The presence of honeycombing on high-resolution computed tomography is a good surrogate for usual interstitial pneumonia and could be utilized in patients unable to undergo surgical lung biopsy. Patients with nonspecific interstitial pneumonia are more likely to respond or remain stable following a course of prednisone. Patients remaining stable following prednisone therapy have the best prognosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866008     DOI: 10.1183/09031936.02.00182002

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  79 in total

1.  [Pulmonary fibrosis. Classification, diagnosis, therapy].

Authors:  U Costabel; J Guzman
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

2.  Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?

Authors:  Kevin R Flaherty; Adin-Cristian Andrei; Talmadge E King; Ganesh Raghu; Thomas V Colby; Athol Wells; Nadir Bassily; Kevin Brown; Roland du Bois; Andrew Flint; Steven E Gay; Barry H Gross; Ella A Kazerooni; Robert Knapp; Edmund Louvar; David Lynch; Andrew G Nicholson; John Quick; Victor J Thannickal; William D Travis; James Vyskocil; Frazer A Wadenstorer; Jeffrey Wilt; Galen B Toews; Susan Murray; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

Review 3.  Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.

Authors:  Michael B Gotway; Michelle M Freemer; Talmadge E King
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

4.  Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.

Authors:  Harold R Collard; James E Loyd; Talmadge E King; Lisa H Lancaster
Journal:  Respir Med       Date:  2007-05-16       Impact factor: 3.415

5.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

6.  The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Lyrica Xiaohong Liu; Caroline Motika; Ella A Kazerooni; Barry H Gross; William D Travis; Thomas V Colby; Susan Murray; Galen B Toews; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2008-12-12       Impact factor: 21.405

7.  Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.

Authors:  Jennifer M Wang; Scott H Robertson; Ziyi Wang; Mu He; Rohan S Virgincar; Geoffry M Schrank; Rose Marie Smigla; Thomas G O'Riordan; John Sundy; Lukas Ebner; Craig R Rackley; Page McAdams; Bastiaan Driehuys
Journal:  Thorax       Date:  2017-08-31       Impact factor: 9.139

8.  Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling.

Authors:  Margaret L Salisbury; Meng Xia; Susan Murray; Brian J Bartholmai; Ella A Kazerooni; Catherine A Meldrum; Fernando J Martinez; Kevin R Flaherty
Journal:  Respir Med       Date:  2016-07-28       Impact factor: 3.415

9.  A possible role of galectin-9 in the pulmonary fibrosis of patients with interstitial pneumonia.

Authors:  Nobuhiro Matsumoto; Shigeki Katoh; Shigehisa Yanagi; Yasuji Arimura; Masatoshi Tokojima; Masaki Ueno; Mitsuomi Hirashima; Masamitsu Nakazato
Journal:  Lung       Date:  2013-01-16       Impact factor: 2.584

10.  Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Fernando J Martinez; Lyrica X Liu; Susan Murray; Meilan K Han; Ella A Kazerooni; Barry H Gross; Jeffrey Myers; William D Travis; Thomas V Colby; Galen B Toews; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2010-01-07       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.